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This PhD thesis research project is aimed at investigating the role of micronutrients in Amyotrophic Lateral 
Scelrosis. Their levels will be correlated with the disease status to evaluate how micronutrients and their 
regulatory pathways could influence the manifestation and the difference of clinical signs of disease in pre-
symptomatic subjects thus explaining the wide phenotypic spectrum of disease. This will be performed through 
different approaches: clinical, biochemical and genetic in order to obtain a nutritional outcome. This could help 
to elucidate the role of micronutrients and its metabolism in the pathogenesis and/or in the progression of ALS. 
Il Ruolo Dei Micronutrienti In Una Malattia Neurodegenerativa Come La Sclerosi 
Laterale Amiotrofica 
Questo progetto di tesi di dottorato si propone di indagare il ruolo dei micronutrienti nella Sclerosi Laterale 
Amiotrofica. Durante questo studio si cercherà di correlarne i livelli corporei con lo stato di malattia in termini di 
età di esordio e prognosi e di valutare come essi potrebbero influenzare la manifestazione e l’eterogeneità di 
segni clinici di malattia. Questo verrà effettuato con diversi approcci: clinici, biochimici e genetici al fine di 
valutarne l’apporto nutrizionale. Ciò potrebbe contribuire a chiarire il ruolo dei micronutrienti e dei loro 
meccanismi di regolazione nella patogenesi e/o nella progressione della SLA. 
1. State-of-the-Art 
Amyotrophic Lateral Sclerosis (ALS) is a rare neurodegenerative disorder with an incidence of about 1/100.000 
case per year. This progressive disease is characterized by a selective degeneration of both upper and lower 
motor neurons in the brain, brainstem and spinal cord resulting in paralysis due to muscle weakness and atrophy, 
leading to death in 3-5 years since the first manifestations of symptoms (Mitchell et al., 2007). In a small 
percentage of the cases, dementia is observed.  
Genetic and environmental factors are involved in the pathogenesis of this complex disease. In familial forms, 
mutations in several genes have been found segregating with the pathology in dominant, recessive and X-Linked 
pattern, giving to ALS the characteristic of an oligogenic disease. 
Neurodegenerative disorders such as ALS have been linked to iron and metals metabolism in different studies 
through the years (Crichton et al., 2006; Hadzhieva et al., 2013). Transition metal induced toxicity has been 
proposed to be involved in ALS (Carrì et al., 2003) and higher concentrations of metals and proteins that 
regulate metal homeostasis have been described in ALS patients (Roos et al., 2012). However, it is difficult to 
establish the real role of metals in ALS aetiology and progression since, when the pathology is diagnosed, all the 
motoneurons are already dead. In this context when we analyze micronutrients we don’t know if we are 
measuring something that is partial cause of disease or if we are observing the endpoint of an unknown process 
started years before. Moreover the iron content of formulas usually employed in ALS Home Enteral Nutrition is 
significantly higher than the recommended daily intake for healthy individuals. Thus this PhD project will aim to 
disclose the role of micronutrients in ALS in a cohort of patients bearing all the same mutation in TARDBP 
gene. This mutation leads to heterogeneous phenotypes (typical ALS, FTD, ALS and FTD, no symptoms) even 
in subjects with comparable ages.  
Table 1 Main ALS causative genes 
Gene Locus Inheritance Prevalence in fALS (%) Clinical features 
C9ORF72 9q21.2-p13.3 AD 35 ALS with FTD 
SOD1 21q22.1 AD/AR 20 Typical ALS 
FUS/TLS 16q12 AD/AR 4 Typical ALS 
TARDBP 1p36 AD 5 ALS with FTD 
VCP 9p13.3 AD 1-2 Adult onset, with or without FTD 
UBQLN2 Xp11.21 X-linked Rare UMN signs proceeding LMN signs 
AD: Autosomal Dominant; AR: Autosomal Recessive; fALS: Familiar Amyotrophic Lateral Sclerosis;  
FTD: Fronto-Temporal Dementia; UMN: Upper Motor Neuron; LMN: Lower Motor Neuron 
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These subjects have a common geographical origin in a geographical restricted area (Acese - Catania), they share 
common diet, water and environment exposure. 
The analysis of micronutrients’ concentrations, the evaluation of proteins that are involved in their homeostasis 
and the genetic analysis of the genes coding for these proteins, in different subjects with an heterogeneous 
phenotype, could help to clarify the effective role of micronutrients in ALS. Recent studies indicate that the  
properties of Epigallocatechin Gallate may account for its neuroprotective capacity (Mandel et al., 2004). A 
previous study performed on transgenic mouse model of ALS showed that an oral treatment with EGCG should 
improve clinical symptoms (Zhihao et al., 2006). Dietary implementation of these natural iron chelators should 
be taken into account as a strategy to prevent iron overload in relatives of patients with ALS, bearing the same 
mutation, without clinical symptoms. 
2. PhD Thesis Objectives and Milestones 
Within the overall objective mentioned above this PhD thesis project can be subdivided into the following 
activities according to the Gantt diagram given in Table 2:  
A1) Sample collection of blood, urine and liquor when available, of patients belonging to the cohort in analysis 
comprising mutated symptomatic patients, mutated asymptomatic patients and non mutated patients. All the 
mutated patients share the same mutation in TARDBP gene. Samples will be collected every 6 months. 
A2) Biochemical analysis to evaluate micronutrients (Fe, Cu, Zn, Al, Mn) concentrations by ICP-MS in 
available biological fluids (A2.1) and plasmatic concentrations of Ferritin, Transferrin, Ceruloplasmin and 
Lactoferrin by 2D-Electrophoresis and Mass Spectrometry (A2.2). Measurements will be performed after 
each sample collection. Statistical analysis to assess any correlation of data obtained with the presence of 
the mutation in TARDBP and other vital parameters (A2.3).  
A3) Genetic analysis of Hemocromatosis (HFE) will be performed in order to exclude that high levels of iron 
are attributable to variants in this gene by FRET technology (A3.1). DNA extraction, PCR amplification 
and sequencing of genes coding for the previously mentioned proteins will be performed with specific 
primers flanking the coding exons and the regulatory regions (A3.2). 
A4) Cellular model will be created by transfecting transiently with either the wild type and the TARDBP 
mutated gene a human neuronal cellular model (SH-SY5Y neuroblastoma) (A4.1). Evaluation of 
expression and regulation of different intracellular proteins will be performed on this model (A4.2). 
A6) Writing and Editing of the PhD thesis, scientific papers and oral and/or poster communications. 
Table 2 Gantt diagram for this PhD thesis project. 
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